1. Hang A, Feldman S, Amin AP, Ochoa JAR, Park SS. Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders.Pharmaceuticals. 2023;16(8):1140.
2. You QS, Gaber R, Meshi A, et al. High-dose high-frequency afliberceptfor recalcitrant neovascular age-related macular degeneration. Retina.2018;38(6):1156-1165.
3. Çıtırık M, İlhan Ç, Teke MY. Yaş tip (neovasküler) yaşa bağlı maküladejenerasyonunda aflibercept tedavisi ve tedavi algoritmaları. GüncelRetina. 2017;1(3):198-205.
4. Gupta A. Bench-to-Bedside Research in Ophthalmology. In: Sobti R,Ganju AK, eds. Biomedical Translational Research. Springer: 2022:67-124.
5. Wykoff CC, Brown DM, Reed K, et al. Effect of high-dose intravitrealaflibercept, 8 mg, in patients with neovascular age-related maculardegeneration: the phase 2 CANDELA randomized clinical trial. JAMAOphthalmol. 2023;141(9):834-842.
6. Lanzetta P. Intravitreal aflibercept injection 8 mg for nAMD: 48-week results from the phase 3 PULSAR trial. American Academy ofOphthalmology 2022 Annual Meeting, September 30-October 3, 2022.Accessed November29,2022. https://investor.regeneron.com/static-files/e3307e7d-d495-438c-b8bb-c62cdacdb375
7. Brown DM. Intravitreal aflibercept injection 8 mg for DME: 48-weekresults from the phase 2/3 PHOTON trial. American Academy ofOphthalmology 2022 Annual Meeting, September 30-October 3, 2022.Accessed November 29, 2022. https://investor.regeneron.com/static-files/da20405e-b843-402e-855b-d824a15dec60
8. U.S. National Library of Medicine. A study to learn how well a higheramount of aflibercept given as an injection into the eye works andhow safe it is in people with reduced vision due to swelling in themacula, central part of the retina caused by a blocked vein in theretina (macula edema secondary to retinal vein occlusion) (QUASAR).Clinicaltrials.gov identifier: NCT05850520. Updated December 28,2023. Accessed January 01, 2024. https://classic.clinicaltrials.gov/ct2/show/NCT05850520
9. Nielsen JS, Roberts CL, Saggau DD, Alliman KJ. High-dose afliberceptfor neovascular AMD and DME in suboptimal responders to standard-dose aflibercept. J Vitreoretin Dis. 2023;7(2):116-124.